BRCA2 and breast cancer: Using genome-wide shRNA screening in BRCA2 ovarian (PEO1) and BC cells (HCC1937, SUM1315MO2, both BRCA1 mutant), it was found that the loss of CHD4 alters the response to cisplatin (63).